| ID | 1187 |
| Name of the vaccine | Sonnei vaccine 1790GAHB |
| Microbe | Bacteria |
| Disease name | Bacillary Dysentery (Shigellosis) |
| Name of bacteria | Shigella genus |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 22 to 50 years |
| Description of the vaccine | Shigella sonnei vaccine. |
| Name of the manufacturer | GlaxoSmithKline |
| Name of the manufacturing country | France |
| Year of manufacture | 2017 |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Three doses, gap of 4 weeks and one booster dose. |
| Mechanism of action | Anti-S. sonnei lipopolysaccharide (LPS) antibody. |
| Route of administration | Intramuscular |
| Indications | Prevents the disease caused by Shigella sonnei. |
| Export | NA |
| Approval | NA |
| Adjuvant | Aluminium hydroxide |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT03089879 |
| Reference | https://adisinsight.springer.com/drugs/800039699 |
| Other name | NA |
| Additional Links | NA
|